Literature DB >> 1659523

Binding specificities and transducing function of the different molecular weight forms of insulin-like growth factor-II (IGF-II) on IGF-I receptors.

J F Perdue1, T R LeBon, J Kato, B Hampton, Y Fujita-Yamaguchi.   

Abstract

In a study that was reported from this laboratory, the mitogenic potency of an apparent mol wt (appMr) of 15,000 precursor form of human insulin-like growth factor-II (hIGF-II) was shown to be greater than that of completely processed hIGF-II for human fetal-derived fibroblasts, and both were more potent than rIGF-I. Since it is generally acknowledged that the stimulation of cell replication by the IGFs is mediated by IGF-I receptors, we undertook to determine whether differences between the receptors' affinity for the two Mr forms of hIGF-II and recombinant IGF-I (rIGF-I) or between its efficiency to couple specific growth factor occupancy to the activation of protein kinase could explain the greater replicating potential of appMr 15,000 hIGF-II. Equilibrium dissociation, i.e. Kd, and inhibition, i.e. Ki, constants were determined by measuring the ability of rIGF-I, hIGF-II, appMr 15,000 hIGF-II, insulin, and the antireceptor monoclonal antibody alpha IR-3 to compete with 125I-labeled rIGF-I and hIGF-II for binding to purified preparations of IGF-I receptors prepared from an enriched source of fetal membrane, i.e. human term placenta. The results of these experiments established that 1) hIGF-II and appMr 15,000 hIGF-II bind to the IGF-I receptor with the same affinity as rIGF-I, e.g. with Kd and Ki values between 0.03-0.07 nM; 2) the total binding capacity, i.e. Ro, for IGF-I binding was not statistically different from the Ro calculated for IGF-II binding; and 3) the statistical analysis of 12 data sets from the competitive binding experiments for goodness of fit indicated that a 1-site model for IGF-I and -II binding was a better fit of the data than a 2-site model. Measurements of the stimulation of IGF-I receptor autophosphorylation at low ligand concentrations established that appMr 15,000 hIGF-II and hIGF-II were more effective than rIGF-I in coupling receptor occupancy to the activation of its protein kinase. At saturating ligand concentrations, the 3 had similar potencies. The original preparation of appMr 15,000 hIGF-II contains a mixture of forms with acidic isoelectric points (pIs) and was more potent than Mr 7,500 IGF-II in stimulating receptor autophosphorylation. These results are consistent with the relative potencies of this preparation, hIGF-II, and rIGF-I in stimulating the replication of 12-week-old fetal dermal fibroblasts.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659523     DOI: 10.1210/endo-129-6-3101

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  Differential insulin-like growth factor II (IGF-II) expression: A potential role for breast cancer survival disparity.

Authors:  S Kalla Singh; Q W Tan; C Brito; M De León; C Garberoglio; D De León
Journal:  Growth Horm IGF Res       Date:  2010-01-25       Impact factor: 2.372

Review 2.  The Emerging Role of Glucose Metabolism in Cartilage Development.

Authors:  Judith M Hollander; Li Zeng
Journal:  Curr Osteoporos Rep       Date:  2019-04       Impact factor: 5.096

3.  Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells.

Authors:  S Kalla Singh; D Moretta; F Almaguel; N R Wall; M De León; D De León
Journal:  Growth Factors       Date:  2007-12       Impact factor: 2.511

4.  Insulin-like growth factor-II gene expression in a rat insulin-producing beta-cell line (INS-1) is regulated by glucose.

Authors:  M Asfari; W De; M Nöel; P E Holthuizen; P Czernichow
Journal:  Diabetologia       Date:  1995-08       Impact factor: 10.122

5.  Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor.

Authors:  L Xiong; J Kasuya; S L Li; J Kato; Y Fujita-Yamaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.